The Latest Breaking News from Path

Nipah is a deadly virus with no vaccine or cure and considered a high-risk pathogen by the World Health Organization

Growth and mid-cap stocks with real earnings power and improving fundamentals tend to outperform when market leadership broadens beyond mega-caps.

Shares of UiPath Inc. (NYSE:PATH) rose sharply in pre-market trading after the company reported upbeat third-quarter financial results and issued fourth-quarter sales guidance with its midpoint above estimates.

U.S. private employers unexpectedly cut 32,000 jobs in November, reversing October's gains and signaling renewed labor-market weakness. ADP's data showed broad declines led by small businesses and major sectors like manufacturing and professional services, while pay growth continued to slow. The softer report boosted market expectations for another Fed rate…

Joel Holsinger, a partner at Ares Management Corp., on Wednesday launched Promote Giving, an initiative encouraging investment managers to donate a portion of their fees to charity

On CNBC's “Mad Money Lightning Round,” Jim Cramer said he can't recommend UiPath Inc. (NYSE:PATH) as the stock just had such a big move. “It's not for me,” he added.

UiPath, Inc. (NYSE:PATH) shares climbed 40% this week on a series of major positive catalysts including new partnerships and industry recognition. 

UiPath Inc. (NYSE:PATH) saw its stock rise 7.70% in pre-market trading on Thursday, reaching $16.79.

Editor’s Note: The future prices of benchmark tracking ETFs were updated in the story.